On Tuesday, Colgate-Palmolive Company (NYSE:CL)’s shares declined -0.25% to $66.73.
Colgate-Palmolive Company (CL)’s Franck Moison, Chief Operating Officer, Emerging Markets & Business Development, will present on Tuesday, June 9, 2015 at the Deutsche Bank Global Consumer Conference in Paris at 12:00 p.m. (6:00 a.m. ET).
Colgate-Palmolive Company, together with its auxiliaries, manufactures and markets consumer products worldwide. It operates in two segments: Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, counting toothpastes, toothbrushes, and mouthwashes, in addition to pharmaceutical products for dentists and other oral health professionals; personal care products comprising liquid hand soaps, shower gels, bar soaps, deodorants, antiperspirants, shampoos, and conditioners; and home care products, such as dishwashing liquids, laundry and dishwashing detergents, household cleaners, oil soaps, bleaches, fabric conditioners, and other products.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)’s shares gained 0.45% to $60.58.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) declared the launch of the generic equivalent to INTUNIV® (guanfacine) 1 mg, 2 mg, 3 mg, and 4 mg, in the United States. Guanfacine extended-release tablets are a nonstimulant medication for the treatment of attention deficit hyperactivity disorder (ADHD) that can be used alone, or as an add-on to stimulant medications.
ADHD is the most common neurobehavioral disorder diagnosed in children in the United States. ADHD affects 1 in 10 U.S. children and half of these children are diagnosed by the age of six.
“Guanfacine extended-release tablets join Teva’s current generic line of seven ADHD products,” commented Brendan O’Grady, President and CEO, North America Generic Medicines. “We recognize the need to make affordable generic treatment options accessible to patients with ADHD.”
INTUNIV® (guanfacine) 1 mg, 2 mg, 3 mg, and 4 mg, had total market sales of about $804 million in the United States, according to IMS data as of March 2015.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients.
At the end of Tuesday’s trade, Express, Inc. (NYSE:EXPR)‘s shares dipped -0.79% to $17.67.
Express, Inc. (EXPR) declared its financial results for the first quarter of 2015. These results cover the thirteen week period ended May 2, 2015.
First Quarter 2015 Operating Results:
- Net sales raised 9% to $502.4 million from $460.7 million in the first quarter of 2014.
- Comparable sales (counting e-commerce sales) raised 7%.
- E-commerce sales rose 12% to $77.6 million.
- Merchandise margin grew by 200 basis points, primarily attributable to better acceptance of our product assortment in addition to a more restrained use of promotions contrast to last year’s first quarter. Buying and occupancy as a percent of net sales improved by 130 basis points as costs were leveraged against a larger revenue base. In combination, this resulted in a gross margin improvement of 330 basis points, with gross margin of 33.1% contrast to 29.8% in last year’s first quarter.
- Selling, general, and administrative (SG&A) expenses were $133.2 million as compared to $122.9 million in last year’s first quarter, primarily due to the timing of certain marketing activities and various payroll related expenses. As a percentage of net sales, SG&A expenses reduced by 20 basis points to 26.5% contrast to 26.7% in last year’s first quarter.
Express, Inc. operates as a specialty apparel and accessories retailer. It offers apparel and accessories for women and men between 20 and 30 years across various aspects of lifestyles, counting work, casual, jeanswear, and going-out occasions. The company sells its products through its e-commerce Website, express.com, in addition to franchisees Express locations in Latin America, the Middle East, and South Africa.
Hanesbrands Inc. (NYSE:HBI), ended its Tuesday’s trading session with -0.66% loss, and closed at $31.81.
Hanesbrands Inc. (HBI) declared recently that it has awarded Wake Forest Baptist Medical Center and its medical professionals with the company’s first Hanes for Good Champion Award for outstanding commitment to community service.
Hanes has partnered with the medical center since 2012 to conduct eight volunteer surgical missions to the Dominican Republic where Hanes has more than 8,000 employees. The medical center’s otolaryngology medical teams have performed more than 500 life-altering ear, nose and throat surgeries and have treated more than 4,000 patients.
Hanes, a leader in corporate social responsibility in the apparel industry, honored Wake Forest Baptist, its medial teams and two Hanes employee volunteers at the company’s annual leadership meeting being held in Winston-Salem and attended by more than 600 Hanes professionals.
Hanesbrands Inc., a consumer goods company, designs, manufactures, sources, and sells a range of basic apparels for men, women, and children in the United States. The company operates through four segments: Innerwear, Activewear, Direct to Consumer, and International. It sells bras, panties, shapewears, hosiery, men’s underwear, children’s underwear, and socks; and other activewear, such as T-shirts, fleece, sport shirts, performance T-shirts and shorts, sports bras, and thermals, in addition to licensed logo apparel in collegiate bookstores and other channels.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
